Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics is a clinical-stage biopharmaceutical company that has the potential to generate significant value for investors due to their strong scientific understanding of integrin biology and their novel integrin-targeted drug delivery platform, which has shown promising results in early clinical trials. With a highly experienced management team and a focused approach on developing therapies for integrin-related diseases, such as solid tumors, Pliant Therapeutics is well positioned to successfully bring its pipeline of treatments to market. However, there are still potential risks, such as clinical and regulatory hurdles, that could impact the company's progression in the near future.

Bears say

Pliant Therapeutics is facing significant hurdles with its lead product candidate PLN-101095 as it is only in Phase I of clinical trials with no indication of future success. The company is also facing financial risks with a high burn rate and limited funding, leading to potential dilution for investors. Additionally, Pliant is dependent on the success of its integrin-based platform and has no other products in its pipeline, putting all its eggs in one basket. The recent announcement of a Phase Ib trial for PLN-101095 is promising, but the company's long timeline for potential success, financial risks, and lack of diversification in its pipeline make it a high-risk investment option. These factors, combined with the competitive landscape for integrin-based therapies, suggest a negative outlook for Pliant Therapeutics' stock.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.